Compare · STVN vs WST
STVN vs WST
Side-by-side comparison of Stevanato Group S.p.A. (STVN) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STVN and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.19B, about 3.9x STVN ($5.96B).
- Over the past year, STVN is down 23.4% and WST is up 27.6% - WST leads by 51.0 points.
- WST has been more active in the news (6 items in the past 4 weeks vs 1 for STVN).
- STVN has more recent analyst coverage (22 ratings vs 18 for WST).
- Company
- Stevanato Group S.p.A.
- West Pharmaceutical Services Inc.
- Price
- $19.76+1.78%
- $328.35-7.74%
- Market cap
- $5.96B
- $23.19B
- 1M return
- +14.75%
- -3.45%
- 1Y return
- -23.40%
- +27.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 6
- Recent ratings
- 22
- 18
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest STVN
- Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
- Director Balachandran Madhavan was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 5% to 69,458 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Dal Lago Marco was granted 2,356 units of Ordinary Shares and converted options into 7,997 units of Ordinary Shares, increasing direct ownership by 14% to 85,353 units (SEC Form 4)
- Director Lin Sue-Jean was granted 4,975 units of Ordinary Shares, increasing direct ownership by 249% to 6,975 units (SEC Form 4)
- Director Morel Donald E Jr was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 10% to 37,424 units (SEC Form 4) (tax withholding)
- Director Santel Luciano was granted 4,975 units of Ordinary Shares, increasing direct ownership by 278% to 6,762 units (SEC Form 4)
- Director Magistretti Elisabetta was granted 4,975 units of Ordinary Shares (SEC Form 4)
- Officer Stocchi Mauro was granted 2,101 units of Ordinary Shares and converted options into 6,586 units of Ordinary Shares, increasing direct ownership by 2% to 413,629 units (SEC Form 4)
- Director Flynn Karen was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 153% to 5,757 units (SEC Form 4) (tax withholding)
- Director Federici William J was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 15% to 26,991 units (SEC Form 4) to satisfy withholding obligation
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target